Tudor Investment Corp ET AL Buys New Shares in Simulations Plus, Inc. $SLP

Tudor Investment Corp ET AL bought a new position in shares of Simulations Plus, Inc. (NASDAQ:SLP) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 120,101 shares of the technology company’s stock, valued at approximately $1,810,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Tributary Capital Management LLC lifted its stake in Simulations Plus by 214.7% in the third quarter. Tributary Capital Management LLC now owns 1,136,980 shares of the technology company’s stock valued at $17,134,000 after acquiring an additional 775,704 shares during the last quarter. Ameriprise Financial Inc. increased its stake in shares of Simulations Plus by 25.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 875,447 shares of the technology company’s stock worth $15,277,000 after purchasing an additional 176,747 shares during the last quarter. First Light Asset Management LLC raised its holdings in shares of Simulations Plus by 115.0% in the 3rd quarter. First Light Asset Management LLC now owns 767,760 shares of the technology company’s stock valued at $11,570,000 after purchasing an additional 410,603 shares during the period. Geode Capital Management LLC raised its holdings in shares of Simulations Plus by 3.1% in the 2nd quarter. Geode Capital Management LLC now owns 397,851 shares of the technology company’s stock valued at $6,943,000 after purchasing an additional 12,003 shares during the period. Finally, Stephens Investment Management Group LLC lifted its stake in Simulations Plus by 46.3% in the 3rd quarter. Stephens Investment Management Group LLC now owns 392,840 shares of the technology company’s stock valued at $5,920,000 after purchasing an additional 124,264 shares during the last quarter. 78.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on SLP. BTIG Research cut Simulations Plus from a “buy” rating to a “neutral” rating in a report on Thursday, December 18th. Citigroup restated a “market perform” rating on shares of Simulations Plus in a research note on Tuesday, January 6th. Zacks Research cut Simulations Plus from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 2nd. TD Cowen reiterated a “hold” rating on shares of Simulations Plus in a research note on Thursday, January 8th. Finally, Wall Street Zen raised Simulations Plus from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Three analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Simulations Plus has a consensus rating of “Hold” and an average price target of $25.00.

Simulations Plus Stock Performance

Shares of SLP stock opened at $11.42 on Friday. Simulations Plus, Inc. has a 52 week low of $11.16 and a 52 week high of $36.45. The company has a market capitalization of $230.08 million, a price-to-earnings ratio of -3.57 and a beta of 1.17. The company has a 50-day simple moving average of $13.93 and a 200 day simple moving average of $16.16.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings results on Thursday, January 8th. The technology company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.05). The company had revenue of $18.42 million during the quarter, compared to the consensus estimate of $18.05 million. Simulations Plus had a negative net margin of 81.66% and a positive return on equity of 14.02%. During the same period in the prior year, the company earned $0.17 earnings per share. Sell-side analysts forecast that Simulations Plus, Inc. will post 1.09 EPS for the current year.

About Simulations Plus

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.